– Reuters
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $278
Piper Sandler analyst Christopher Raymond maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $265 to $278.
Related Posts
China Evergrande Files For Chapter 15 Bankruptcy Protection In US
China’s Most Indebted Property Developer, China Evergrande Group (OTC:EGRNF), has Filed For Chapter 15 Bankruptcy Protection In A…
Why Airbnb Stock Is Moving Lower
Airbnb Inc (NASDAQ: ABNB) shares are trading lower Wednesday after the company reported worse-than-expected top line results. Several analysts also lowered price targets on the stock.
Why Skyline Champion Shares Are Diving Today
Factory-built housing company Skyline Champion Corporation (NYSE:SKY) reported the fourth quarter FY23 sales of $491.53 million, missing the consensus estimate of $528.22…